Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander E Perl

Showing results (51-60 of 88) with videos related to

Pageof 9
Sort By:
American Journal of Hematology|April 4, 2020
Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agentsGee Youn Geeny Kim, Jonathan Burns, Craig W Freyer, et al.
American Journal of Hematology|February 12, 2024
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centersYasmin Abaza, Eric S Winer, Guru Subramanian Guru Murthy, et al.
Haematologica|March 13, 2025
Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trialRichard F Schlenk, Pau Montesinos, Hee-Je Kim, et al.
Blood|January 26, 2022
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trialAlexander E Perl, Richard A Larson, Nikolai A Podoltsev, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2019
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic LeukemiaNoelle V Frey, Pamela A Shaw, Elizabeth O Hexner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2023
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AMLKeith W Pratz, Mohamad Cherry, Jessica K Altman, et al.
Leukemia & Lymphoma|February 21, 2022
Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamideCraig W Freyer, Alison Carulli, Shannon Gier, et al.
Blood Advances|August 21, 2024
Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemiaBetty K Hamilton, Bhavik J Pandya, Cristina Ivanescu, et al.
Transplantation and Cellular Therapy|May 9, 2021
Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of StayCraig W Freyer, Shannon Gier, Mary E Moyer, et al.
Transplantation and Cellular Therapy|December 16, 2022
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage ChemotherapyAlexander E Perl, Richard A Larson, Nikolai A Podoltsev, et al.
Pageof 9

Showing results (51-60 of 88) with videos related to

Sort By:
Pageof 9
American Journal of Hematology|April 4, 2020
Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agentsGee Youn Geeny Kim, Jonathan Burns, Craig W Freyer, et al.
American Journal of Hematology|February 12, 2024
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centersYasmin Abaza, Eric S Winer, Guru Subramanian Guru Murthy, et al.
Haematologica|March 13, 2025
Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trialRichard F Schlenk, Pau Montesinos, Hee-Je Kim, et al.
Blood|January 26, 2022
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trialAlexander E Perl, Richard A Larson, Nikolai A Podoltsev, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2019
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic LeukemiaNoelle V Frey, Pamela A Shaw, Elizabeth O Hexner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2023
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AMLKeith W Pratz, Mohamad Cherry, Jessica K Altman, et al.
Leukemia & Lymphoma|February 21, 2022
Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamideCraig W Freyer, Alison Carulli, Shannon Gier, et al.
Blood Advances|August 21, 2024
Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemiaBetty K Hamilton, Bhavik J Pandya, Cristina Ivanescu, et al.
Transplantation and Cellular Therapy|May 9, 2021
Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of StayCraig W Freyer, Shannon Gier, Mary E Moyer, et al.
Transplantation and Cellular Therapy|December 16, 2022
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage ChemotherapyAlexander E Perl, Richard A Larson, Nikolai A Podoltsev, et al.
Pageof 9